SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Sun Yat-sen Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSun Yat-sen
Date of birth1866-11-12
IdentifiersMRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183
Document date2026-11-01
AuthorWen-Li Huang, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient with a right upper abdominal mass, aching and weight loss: work-up of a liver mass, symptom care, and how he wants to receive results. Concerns: He has had a dull ache under his right ribs, early fullness and weight loss for three months, and can feel a firm lump there himself; As a physician by training he wants to see his images and results himself, to be told plainly, and to be cared for on the same pathway as any other patient; He wants to keep working and traveling for as long as he can. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a dayTwo tablets by mouth every 8 hours as needed, no more than 3,000 mg a dayOral route1924-05-04activeS
Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cyclesIntravenous route1924-06-01activeS
Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cycles, with hydrationIntravenous route1924-06-01activeS
Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycleDay 1 of each 21-day cycle with chemotherapy, then every 4 weeks aloneIntravenous route1924-06-01activeS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet by mouth every 8 hours as needed for nauseaOral route1924-06-01activeS
Magnesium oxide 400 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1924-10-26activeS

Procedures

ProcedureDatesStatusEvidence
Ultrasound of the abdomen1924-05-04 to 1924-05-04completedS
Multiphase contrast CT of the liver with CT of the chest, abdomen and pelvis1924-05-07 to 1924-05-07completedS
MRI of the liver with MRCP1924-05-11 to 1924-05-11completedS
Ultrasound-guided core biopsy of the liver mass1924-05-13 to 1924-05-13completedS
Multidisciplinary hepatobiliary tumor board review before staging1924-05-20 to 1924-05-20completedS
Staging laparoscopy1924-05-27 to 1924-05-27completedS
Biopsy of peritoneal nodules at staging laparoscopy1924-05-27 to 1924-05-27completedS
Implanted venous access port placed under the same anesthetic1924-05-27 to 1924-05-27completedS
Multidisciplinary hepatobiliary tumor board review after staging laparoscopy1924-05-29 to 1924-05-29completedS
Restaging contrast CT of the chest, abdomen and pelvis after three cycles1924-07-30 to 1924-07-30completedS
Restaging contrast CT of the chest, abdomen and pelvis after seven cycles1924-10-22 to 1924-10-22completedS
Advance care planning conversation, about 25 minutes1924-09-21 to 1924-09-21completedS

Immunizations

DateVaccineStatusEvidence
1924-09-21Influenza vaccine, 1924-1925 season (inactivated)completedS
1924-09-21COVID-19 vaccine, 1924-1925 formulacompletedS
1924-09-21Pneumococcal conjugate vaccine (PCV20), for immunosuppression by chemotherapycompletedS
1924-10-26Recombinant zoster vaccine, first of two dosescompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

No historical medical events are recorded.

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
He has had a dull ache under his right ribs, early fullness and weight loss for three months, and can feel a firm lump there himselfactiveS
As a physician by training he wants to see his images and results himself, to be told plainly, and to be cared for on the same pathway as any other patientactiveS
He wants to keep working and traveling for as long as he canactiveS

Assessment

Most recent measures: Leukocytes [#/volume] in Blood by Automated count 3.9 on 1924-09-02; Hemoglobin [Mass/volume] in Blood 10.6 on 1924-09-02; Platelets [#/volume] in Blood by Automated count 162 on 1924-09-02; Sodium [Moles/volume] in Serum or Plasma 137 on 1924-10-26; Potassium [Moles/volume] in Serum or Plasma 4.1 on 1924-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.95 on 1924-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M 93 on 1924-10-26; Glucose [Mass/volume] in Serum or Plasma 96 on 1924-10-26; Albumin [Mass/volume] in Serum or Plasma 3.7 on 1924-10-26; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 1924-10-26; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 141 on 1924-10-26; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 1924-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 on 1924-10-26; INR in Platelet poor plasma by Coagulation assay 1 on 1924-05-04; Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 3.2 on 1924-05-04; Cancer Ag 19-9 [Units/volume] in Serum or Plasma 121 on 1924-10-26; Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 8.6 on 1924-05-04; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1924-09-21; ECOG Performance Status score 1 on 1924-10-26; Neutrophils [#/volume] in Blood by Automated count 1.6 on 1924-09-02; Magnesium [Mass/volume] in Serum or Plasma 1.6 on 1924-10-26; Thyrotropin [Units/volume] in Serum or Plasma 3.1 on 1924-10-26; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 1924-10-26 [S]

Strengths and supports: Strengths and supports: a clear, analytical mind and his own medical training; a strong sense of purpose in his work; a wide circle of colleagues [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arrangedresolvedconfirmed R19.01S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis.
Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinomaactiveconfirmed C23S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy.
Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitoredactiveconfirmed Z86.19S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis.
Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectableactiveconfirmed C78.6S — Synthetic finding anchored to the peritoneal metastases reported at autopsy.
Acute viral upper respiratory infection on day 10 of cycle 5 of chemoimmunotherapy: sore throat, runny nose and dry cough for three days, afebrile, with a neutrophil count of 1.6 x10^3/uL; rapid tests for SARS-CoV-2 and influenza negative; no sign of pneumonia or pneumonitis; resolvedresolvedconfirmed J06.9S — Synthetic acute illness; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1924-05-04Leukocytes [#/volume] in Blood by Automated count7.910*3/uL4-11 10*3/uLNormalS
1924-05-04Hemoglobin [Mass/volume] in Blood12.6g/dL13.2-17.1 g/dLLowS
1924-05-04Platelets [#/volume] in Blood by Automated count34210*3/uL150-400 10*3/uLNormalS
1924-05-04Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1924-05-04Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1924-05-04Creatinine [Mass/volume] in Serum or Plasma0.86mg/dL0.74-1.35 mg/dLNormalS
1924-05-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1924-05-04Glucose [Mass/volume] in Serum or Plasma98mg/dL70-99 mg/dLNormalS
1924-05-04Albumin [Mass/volume] in Serum or Plasma3.4g/dL3.5-5 g/dLLowS
1924-05-04Bilirubin.total [Mass/volume] in Serum or Plasma0.9mg/dL0.2-1.2 mg/dLNormalS
1924-05-04Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma212U/L40-129 U/LHighS
1924-05-04Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma48U/L10-40 U/LHighS
1924-05-04Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L7-55 U/LNormalS
1924-05-04INR in Platelet poor plasma by Coagulation assay1{INR}0.9-1.1NormalS
1924-05-04Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma3.2ng/mL<=8.3 ng/mLNormalS
1924-05-04Cancer Ag 19-9 [Units/volume] in Serum or Plasma412U/mL<=35 U/mLHighS
1924-05-04Carcinoembryonic Ag [Mass/volume] in Serum or Plasma8.6ng/mLUp to 3.0 ng/mL in non-smokersHighS
1924-05-04Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1924-05-04ECOG Performance Status score1{score}S
1924-05-18ECOG Performance Status score1{score}S
1924-06-01Leukocytes [#/volume] in Blood by Automated count7.410*3/uL4-11 10*3/uLNormalS
1924-06-01Neutrophils [#/volume] in Blood by Automated count4.910*3/uL1.8-7.7 10*3/uLNormalS
1924-06-01Hemoglobin [Mass/volume] in Blood12.2g/dL13.2-17.1 g/dLLowS
1924-06-01Platelets [#/volume] in Blood by Automated count31810*3/uL150-400 10*3/uLNormalS
1924-06-01Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1924-06-01Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1924-06-01Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.74-1.35 mg/dLNormalS
1924-06-01Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M102mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1924-06-01Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.7-2.2 mg/dLNormalS
1924-06-01Albumin [Mass/volume] in Serum or Plasma3.4g/dL3.5-5 g/dLLowS
1924-06-01Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.2-1.2 mg/dLNormalS
1924-06-01Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma236U/L40-129 U/LHighS
1924-06-01Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma52U/L10-40 U/LHighS
1924-06-01Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma44U/L7-55 U/LNormalS
1924-06-01Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.45-4.5 mIU/LNormalS
1924-06-01Cancer Ag 19-9 [Units/volume] in Serum or Plasma498U/mL<=35 U/mLHighS
1924-06-01Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1924-06-01ECOG Performance Status score1{score}S
1924-08-03Leukocytes [#/volume] in Blood by Automated count4.610*3/uL4-11 10*3/uLNormalS
1924-08-03Neutrophils [#/volume] in Blood by Automated count2.410*3/uL1.8-7.7 10*3/uLNormalS
1924-08-03Hemoglobin [Mass/volume] in Blood10.9g/dL13.2-17.1 g/dLLowS
1924-08-03Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
1924-08-03Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
1924-08-03Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
1924-08-03Creatinine [Mass/volume] in Serum or Plasma0.92mg/dL0.74-1.35 mg/dLNormalS
1924-08-03Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M97mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1924-08-03Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
1924-08-03Magnesium [Mass/volume] in Serum or Plasma1.7mg/dL1.7-2.2 mg/dLNormalS
1924-08-03Albumin [Mass/volume] in Serum or Plasma3.6g/dL3.5-5 g/dLNormalS
1924-08-03Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.2-1.2 mg/dLNormalS
1924-08-03Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma158U/L40-129 U/LHighS
1924-08-03Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma34U/L10-40 U/LNormalS
1924-08-03Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-55 U/LNormalS
1924-08-03Thyrotropin [Units/volume] in Serum or Plasma2.4m[IU]/L0.45-4.5 mIU/LNormalS
1924-08-03Cancer Ag 19-9 [Units/volume] in Serum or Plasma168U/mL<=35 U/mLHighS
1924-08-03Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1924-08-03ECOG Performance Status score1{score}S
1924-10-26Leukocytes [#/volume] in Blood by Automated count4.310*3/uL4-11 10*3/uLNormalS
1924-10-26Neutrophils [#/volume] in Blood by Automated count2.110*3/uL1.8-7.7 10*3/uLNormalS
1924-10-26Hemoglobin [Mass/volume] in Blood10.7g/dL13.2-17.1 g/dLLowS
1924-10-26Platelets [#/volume] in Blood by Automated count17610*3/uL150-400 10*3/uLNormalS
1924-10-26Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1924-10-26Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
1924-10-26Creatinine [Mass/volume] in Serum or Plasma0.95mg/dL0.74-1.35 mg/dLNormalS
1924-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M93mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1924-10-26Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
1924-10-26Magnesium [Mass/volume] in Serum or Plasma1.6mg/dL1.7-2.2 mg/dLLowS
1924-10-26Albumin [Mass/volume] in Serum or Plasma3.7g/dL3.5-5 g/dLNormalS
1924-10-26Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.2-1.2 mg/dLNormalS
1924-10-26Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma141U/L40-129 U/LHighS
1924-10-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L10-40 U/LNormalS
1924-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-55 U/LNormalS
1924-10-26Thyrotropin [Units/volume] in Serum or Plasma3.1m[IU]/L0.45-4.5 mIU/LNormalS
1924-10-26Cancer Ag 19-9 [Units/volume] in Serum or Plasma121U/mL<=35 U/mLHighS
1924-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1924-10-26ECOG Performance Status score1{score}S
1924-09-02Leukocytes [#/volume] in Blood by Automated count3.910*3/uL4-11 10*3/uLLowS
1924-09-02Neutrophils [#/volume] in Blood by Automated count1.610*3/uL1.8-7.7 10*3/uLLowS
1924-09-02Hemoglobin [Mass/volume] in Blood10.6g/dL13.2-17.1 g/dLLowS
1924-09-02Platelets [#/volume] in Blood by Automated count16210*3/uL150-400 10*3/uLNormalS
1924-09-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1924-05-04Body height165cmS
1924-05-04Body weight61kgS
1924-05-04Body mass index (BMI) [Ratio]22.4kg/m2S
1924-05-04Systolic blood pressure132mm[Hg]S
1924-05-04Diastolic blood pressure84mm[Hg]S
1924-05-04Heart rate88/minS
1924-05-04Respiratory rate16/minS
1924-05-04Body temperature36.9CelS
1924-05-04Oxygen saturation in Arterial blood by Pulse oximetry98%S
1924-05-18Body height165cmS
1924-05-18Body weight60.6kgS
1924-05-18Body mass index (BMI) [Ratio]22.3kg/m2S
1924-05-18Systolic blood pressure128mm[Hg]S
1924-05-18Diastolic blood pressure82mm[Hg]S
1924-05-18Heart rate86/minS
1924-05-18Respiratory rate16/minS
1924-05-18Body temperature36.8CelS
1924-05-18Oxygen saturation in Arterial blood by Pulse oximetry98%S
1924-06-01Body height165cmS
1924-06-01Body weight60kgS
1924-06-01Body mass index (BMI) [Ratio]22kg/m2S
1924-06-01Systolic blood pressure126mm[Hg]S
1924-06-01Diastolic blood pressure80mm[Hg]S
1924-06-01Heart rate84/minS
1924-06-01Respiratory rate16/minS
1924-06-01Body temperature36.7CelS
1924-06-01Oxygen saturation in Arterial blood by Pulse oximetry98%S
1924-08-03Body height165cmS
1924-08-03Body weight59.2kgS
1924-08-03Body mass index (BMI) [Ratio]21.7kg/m2S
1924-08-03Systolic blood pressure122mm[Hg]S
1924-08-03Diastolic blood pressure78mm[Hg]S
1924-08-03Heart rate82/minS
1924-08-03Respiratory rate16/minS
1924-08-03Body temperature36.6CelS
1924-08-03Oxygen saturation in Arterial blood by Pulse oximetry98%S
1924-10-26Body height165cmS
1924-10-26Body weight59.6kgS
1924-10-26Body mass index (BMI) [Ratio]21.9kg/m2S
1924-10-26Systolic blood pressure124mm[Hg]S
1924-10-26Diastolic blood pressure78mm[Hg]S
1924-10-26Heart rate80/minS
1924-10-26Respiratory rate16/minS
1924-10-26Body temperature36.6CelS
1924-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S
1924-09-02Body height165cmS
1924-09-02Body weight59kgS
1924-09-02Body mass index (BMI) [Ratio]21.7kg/m2S
1924-09-02Systolic blood pressure120mm[Hg]S
1924-09-02Diastolic blood pressure76mm[Hg]S
1924-09-02Heart rate90/minS
1924-09-02Respiratory rate16/minS
1924-09-02Body temperature37.4CelS
1924-09-02Oxygen saturation in Arterial blood by Pulse oximetry97%S
1924-09-21Body height165cmS
1924-09-21Body weight59.4kgS
1924-09-21Body mass index (BMI) [Ratio]21.8kg/m2S
1924-09-21Systolic blood pressure122mm[Hg]S
1924-09-21Diastolic blood pressure76mm[Hg]S
1924-09-21Heart rate80/minS
1924-09-21Respiratory rate16/minS
1924-09-21Body temperature36.6CelS
1924-09-21Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1924-05-04New patient with a right upper abdominal mass, aching and weight loss: work-up of a liver mass, symptom care, and how he wants to receive resultsfinishedS
1924-05-18Biopsy and imaging results and medical oncology consultation; diagnosis, staging plan, and hepatitis B statusfinishedS
1924-06-01Staging laparoscopy result and tumor board recommendation; first cycle of chemoimmunotherapy and specialist palliative carefinishedS
1924-08-03Before cycle 4: restaging CT, tumor marker, toxicity review, hepatitis B monitoring, and genomic profiling resultfinishedS
1924-10-26Before cycle 8: restaging CT, toxicity review, low magnesium, and the plan for maintenance durvalumabfinishedS
1924-09-02Same-day sick visit for a cold during chemoimmunotherapyfinishedS
1924-09-21Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Work-up of the liver mass: multiphase contrast CT of the liver with CT of the chest, abdomen and pelvis; MRI of the liver with MRCP if CT does not settle the origin; alpha-fetoprotein, CA 19-9 and CEA; hepatitis B surface antigen, core antibody and surface antibody, and hepatitis C antibody; liver function with Child-Pugh and ALBI scoring; and image-guided core biopsy, because a mass in a liver without cirrhosis cannot be diagnosed by imaging alonecompletedGL-AASLD-HCC-2023, GL-NCCN-BIL-2026S
Medical oncology consultation for a solid liver mass with weight loss: diagnosis, staging, multidisciplinary tumor board review, and treatmentcompletedGL-NCCN-BIL-2026, GL-AASLD-HCC-2023S
Symptom care during the work-up: acetaminophen up to 3,000 mg a day, small frequent meals with a dietitian's advice, weight at every visit, and a same-day call for jaundice, fever, vomiting, dark urine or worse pain; results shared with him in full as they arrive, by one coordinating cliniciancompletedGL-NCCN-BIL-2026S
Staging laparoscopy before any attempt at resection, with biopsy of any peritoneal disease and an implanted port under the same anesthetic; if no metastases, extended cholecystectomy with resection of liver segments IVb and V and portal lymphadenectomy; comprehensive genomic profiling of the biopsy tissue (HER2, mismatch repair and microsatellite status, BRAF, FGFR2, IDH1, NTRK, RET, KRAS, tumor mutational burden)completedGL-NCCN-BIL-2026S
Hepatitis B reactivation monitoring for resolved infection (surface antigen negative, core antibody positive, HBV DNA undetectable): HBV DNA and ALT every 3 months during treatment and for at least 6 to 12 months after, with entecavir started promptly if HBV DNA becomes detectable or surface antigen reappearscompletedGL-ASCO-HBV-2020S
First-line systemic therapy for stage IVB gallbladder adenocarcinoma: gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 with durvalumab 1,500 mg on day 1 every 21 days for up to 8 cycles, then durvalumab 1,500 mg every 4 weeks until progression or unacceptable toxicity; blood count, creatinine, magnesium and liver tests before each dose; TSH every cycle; CA 19-9 each cycle; CT of the chest, abdomen and pelvis every 2 to 3 months; teaching on immune-related side effects; ondansetron at homecompletedGL-NCCN-BIL-2026, GL-TOPAZ1-2022, GL-ASCO-IRAE-2021S
Specialist palliative care alongside cancer treatment from the diagnosis of advanced disease: symptoms, nutrition, coping, goals of care, a health care agent, and a family meeting if and when he choosescompletedGL-ASCO-PALL-2017S
Magnesium oxide 400 mg by mouth daily for cisplatin-related low magnesium, rechecked with each dose; durvalumab maintenance every 4 weeks after the eighth cycle, with restaging CT every 2 to 3 monthscompletedGL-NCCN-BIL-2026, GL-TOPAZ1-2022S

Goals

GoalTargetStatusOutcomeProvenance
Tissue diagnosis and complete staging within four weeks of the first visit1924-06-01completedBiopsy diagnosis in nine days and staging complete by laparoscopy in about three and a half weeksS
Right upper abdominal pain at 3 of 10 or less, with full days of work possible (ECOG 0 to 1)1924-10-26completedAche 0 to 2 of 10 on acetaminophen as needed; ECOG 1 throughoutS
Weight held within 2 kg of the weight at the start of treatment1924-10-26completed60.0 kg at cycle 1 and 59.6 kg at cycle 8S
Goals of care and a health care agent documented, and revisited as treatment changes1924-09-21completedAgent named and goals recorded with palliative care and at the preventive visitS
Complete first-line chemoimmunotherapy without grade 3 or higher toxicity1924-10-26activeSeven cycles given by the last visit with grade 1 toxicity only; the eighth started that dayS

Functional Status

Mental Status